AI assistant
Moderna, Inc. — Director's Dealing 2020
Apr 14, 2020
30610_dirs_2020-04-14_cbe09baf-c7f4-4b8b-9534-a48e50766099.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2020-04-13
Reporting Person: Hoge Stephen (President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-04-13 | Common Stock | S | 8951 | $32.33 | Disposed | 2027589 | Direct |
| 2020-04-13 | Common Stock | S | 1049 | $32.90 | Disposed | 2026540 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 4116 | Indirect |
Footnotes
F1: This sale was effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.82 to $32.74. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $32.96. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.